News
We provide the latest news from the world of economics and finance
(RTTNews) - Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company, Wednesday announced that it has appointed Matthew Greenhawt, as its Chief Medical Officer.
According to the company, Greenhawt is an internationally recognized expert in allergy and immunology with particular expertise in food allergy, anaphylaxis, patient-centered care, and health services and health policy research.
He takes over from Gary Slatko who was serving as the interim Chief Medical Officer.
Most recently, Greenhawt served as Chief Medical Officer of the Asthma and Allergy Foundation of America. Prior to this, he was the Professor of Pediatrics at Childrens Hospital Colorado and the University of Colorado School of Medicine.
In pre-market, AQST shares were trading at $3.90, up 0.52% on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2026 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
